ECSP12011907A - Composiciones para tratar naúsea y vómito centralmente mediados - Google Patents

Composiciones para tratar naúsea y vómito centralmente mediados

Info

Publication number
ECSP12011907A
ECSP12011907A ECSP12011907A ECSP12011907A EC SP12011907 A ECSP12011907 A EC SP12011907A EC SP12011907 A ECSP12011907 A EC SP12011907A EC SP12011907 A ECSP12011907 A EC SP12011907A
Authority
EC
Ecuador
Prior art keywords
vomiting
treat
compositions
nause
centrally
Prior art date
Application number
Other languages
English (en)
Inventor
Daniele Bonadeo
Riccardo Braglia
Fabio Trento
Sergio Cantoreggi
Giorgia Rossi
Roberta Cannella
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011907(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of ECSP12011907A publication Critical patent/ECSP12011907A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proveen composiciones y métodos para tratar o prevenir náusea y vómito en pacientes que pasan por quimioterapia, radioterapia o cirugía.
ECSP12011907 2009-11-18 2012-05-17 Composiciones para tratar naúsea y vómito centralmente mediados ECSP12011907A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US38270910P 2010-09-14 2010-09-14

Publications (1)

Publication Number Publication Date
ECSP12011907A true ECSP12011907A (es) 2012-10-30

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011907 ECSP12011907A (es) 2009-11-18 2012-05-17 Composiciones para tratar naúsea y vómito centralmente mediados

Country Status (40)

Country Link
US (1) US12042494B2 (es)
EP (3) EP2361090B1 (es)
JP (1) JP5890780B2 (es)
KR (1) KR101615108B1 (es)
CN (6) CN107050455B (es)
AP (1) AP3083A (es)
AU (1) AU2010320598B2 (es)
BR (1) BR112012011485B1 (es)
CA (1) CA2778301C (es)
CL (1) CL2012001276A1 (es)
CO (1) CO6551693A2 (es)
CR (1) CR20120216A (es)
CU (1) CU24048B1 (es)
CY (1) CY1118062T1 (es)
DK (2) DK2722045T3 (es)
DO (1) DOP2012000138A (es)
EA (1) EA026815B1 (es)
EC (1) ECSP12011907A (es)
ES (4) ES2623503T3 (es)
GE (1) GEP20156226B (es)
GT (1) GT201200156A (es)
HK (2) HK1214148A1 (es)
HR (3) HRP20140759T1 (es)
HU (1) HUE029677T2 (es)
IL (1) IL219576A (es)
LT (1) LT2722045T (es)
MA (1) MA33810B1 (es)
MX (1) MX2012005347A (es)
MY (1) MY159393A (es)
NI (1) NI201200090A (es)
NZ (1) NZ599439A (es)
PE (1) PE20121483A1 (es)
PH (1) PH12012500887A1 (es)
PL (3) PL2722044T3 (es)
PT (2) PT2722045T (es)
RS (2) RS55206B1 (es)
SI (2) SI2361090T1 (es)
SM (1) SMT201400112B (es)
TN (1) TN2012000170A1 (es)
WO (1) WO2011061622A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
HRP20140759T1 (hr) 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
DK2729147T3 (en) 2011-07-04 2017-12-18 Irbm - Science Park S P A NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA
ES2579616T3 (es) * 2011-10-18 2016-08-12 Helsinn Healthcare Sa Combinaciones terapéuticas de netupitant y palonosetrón
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
WO2016141341A1 (en) 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
HRP20250615T1 (hr) * 2017-11-17 2025-07-18 Vanda Pharmaceuticals Inc. Tradipitant za upotrebu u liječenju gastropareze
JP2021512869A (ja) * 2018-02-02 2021-05-20 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 経口製剤及びその使用
MX2023007578A (es) * 2020-12-25 2023-07-06 Shanghai Shengdi Pharmaceutical Co Ltd Uso del compuesto profarmaco antagonista nk1 en combinacion con un antagonista del receptor 5-ht3.
IL321446A (en) 2022-12-12 2025-08-01 Tiefenbacher Alfred E Gmbh & Co Kg Fixed-dose combination including netopitant and flunosterone
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2025246530A1 (en) * 2024-05-30 2025-12-04 The Chinese University Of Hong Kong Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030718C (en) 1989-11-28 1998-05-12 Jacob Berger Tricyclic compounds
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
DE60045564D1 (de) 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
CA2415890C (en) 2000-07-14 2009-04-07 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
DE60123661T2 (de) 2000-12-14 2007-08-16 F. Hoffmann-La Roche Ag Selbstemulgierende lipidmatrix (selm)
CA2505990C (en) 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
BRPI0409128A (pt) * 2003-04-08 2006-03-28 Progenics Pharm Inc uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
CN101128189A (zh) 2005-02-25 2008-02-20 弗·哈夫曼-拉罗切有限公司 药物物质分散性改善的片剂
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CA2642922C (en) 2006-02-23 2011-08-02 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
JP2011505873A (ja) * 2007-12-18 2011-03-03 シェーリング コーポレイション 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
HRP20140759T1 (hr) 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja

Also Published As

Publication number Publication date
CR20120216A (es) 2012-07-24
GEP20156226B (en) 2015-01-26
CN106421793A (zh) 2017-02-22
EP2727590A1 (en) 2014-05-07
CY1118062T1 (el) 2017-06-28
ES2494015T3 (es) 2014-09-12
CA2778301C (en) 2016-06-14
CN106421793B (zh) 2023-06-16
EP2722044B1 (en) 2017-01-04
GT201200156A (es) 2014-03-27
ES2623503T3 (es) 2017-07-11
PE20121483A1 (es) 2012-12-02
CN102655864A (zh) 2012-09-05
DK2361090T3 (da) 2014-08-25
IL219576A0 (en) 2012-06-28
CN104856998A (zh) 2015-08-26
EA201290356A1 (ru) 2012-12-28
HRP20161277T1 (hr) 2016-11-18
KR20120101456A (ko) 2012-09-13
ES2559475T3 (es) 2016-02-12
DK2722045T3 (en) 2016-10-24
CU24048B1 (es) 2014-12-26
SI2361090T1 (sl) 2014-09-30
AU2010320598B2 (en) 2016-06-16
PL2361090T3 (pl) 2014-10-31
HK1214147A1 (zh) 2016-07-22
AP2012006278A0 (en) 2012-06-30
HK1214148A1 (zh) 2016-07-22
HRP20170419T1 (hr) 2017-06-02
RS55206B1 (sr) 2017-01-31
CU20120078A7 (es) 2012-10-15
DOP2012000138A (es) 2012-11-15
PL2722044T3 (pl) 2017-08-31
CN104856999A (zh) 2015-08-26
CN107050455B (zh) 2020-09-29
PT2361090E (pt) 2014-09-03
EA026815B1 (ru) 2017-05-31
ES2595077T3 (es) 2016-12-27
BR112012011485A2 (pt) 2018-04-03
MA33810B1 (fr) 2012-12-03
CA2778301A1 (en) 2011-05-26
CO6551693A2 (es) 2012-10-31
US20230263799A1 (en) 2023-08-24
CN106512010A (zh) 2017-03-22
HUE029677T2 (hu) 2017-03-28
NI201200090A (es) 2012-11-13
CN107050455A (zh) 2017-08-18
US12042494B2 (en) 2024-07-23
WO2011061622A1 (en) 2011-05-26
AP3083A (en) 2015-01-31
EP2727590B1 (en) 2015-10-21
PL2722045T3 (pl) 2017-03-31
SI2722045T1 (sl) 2017-02-28
TN2012000170A1 (en) 2013-12-12
BR112012011485B1 (pt) 2021-06-29
PT2722045T (pt) 2016-10-18
JP5890780B2 (ja) 2016-03-22
SMT201400112B (it) 2014-11-10
EP2361090B1 (en) 2014-05-21
MX2012005347A (es) 2012-08-03
AU2010320598A1 (en) 2012-06-14
JP2013511507A (ja) 2013-04-04
MY159393A (en) 2016-12-30
IL219576A (en) 2017-08-31
KR101615108B1 (ko) 2016-05-12
NZ599439A (en) 2014-06-27
PH12012500887A1 (en) 2016-08-26
LT2722045T (lt) 2016-09-26
CL2012001276A1 (es) 2012-12-07
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
HRP20140759T1 (hr) 2014-10-24
RS53491B1 (sr) 2015-02-27

Similar Documents

Publication Publication Date Title
CO6551693A2 (es) Composiciones para tratar naúseas y vómito centralmente mediados
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
MX2020002867A (es) Inhibidores de glucosilceramida sintasa.
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
ATE528013T1 (de) Impfstoff-zusammensetzungen
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UY32546A (es) Composiciones y metodos para tratar cancer
MX389168B (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CY1115471T1 (el) Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης
TH149036B (th) การบำบัดรักษาแบบสารรวมซึ่งประกอบรวมด้วยตัวยับยั้ง sglt และตัวยับยั้ง dpp4
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO6721062A2 (es) Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek
ECSP13012736A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek